Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023

SELL
$26.74 - $40.81 $327,992 - $500,575
-12,266 Reduced 31.36%
26,851 $717,000
Q2 2023

Aug 07, 2023

SELL
$28.52 - $40.7 $183,440 - $261,782
-6,432 Reduced 14.12%
39,117 $1.45 Million
Q1 2023

May 04, 2023

BUY
$29.39 - $36.27 $581,657 - $717,819
19,791 Added 76.83%
45,549 $1.42 Million
Q4 2022

May 23, 2023

SELL
$29.23 - $40.28 $578,490 - $797,181
-19,791 Reduced 43.45%
25,758 $767,000
Q4 2022

Feb 13, 2023

SELL
$29.23 - $40.28 $811,775 - $1.12 Million
-27,772 Reduced 51.88%
25,758 $767,000
Q3 2022

Nov 03, 2022

SELL
$37.92 - $63.74 $250,006 - $420,237
-6,593 Reduced 10.97%
53,530 $2.04 Million
Q2 2022

Aug 04, 2022

SELL
$47.98 - $62.75 $234,334 - $306,471
-4,884 Reduced 7.51%
60,123 $3.28 Million
Q1 2022

May 05, 2022

BUY
$49.85 - $96.11 $2.75 Million - $5.31 Million
55,212 Added 563.68%
65,007 $4.06 Million
Q4 2021

Feb 07, 2022

BUY
$77.3 - $105.0 $377,069 - $512,190
4,878 Added 99.21%
9,795 $985,000
Q3 2021

Nov 10, 2021

BUY
$74.87 - $110.87 $368,135 - $545,147
4,917 New
4,917 $442,000
Q1 2020

May 12, 2020

SELL
$6.75 - $19.75 $325,410 - $952,127
-48,209 Closed
0 $0
Q3 2019

Nov 13, 2019

SELL
$5.96 - $12.81 $20,645 - $44,373
-3,464 Reduced 6.7%
48,209 $501,000
Q2 2019

Aug 12, 2019

BUY
$4.93 - $7.5 $72,037 - $109,590
14,612 Added 39.43%
51,673 $345,000
Q4 2018

Feb 11, 2019

SELL
$3.12 - $4.09 $110,292 - $144,581
-35,350 Reduced 48.82%
37,061 $117,000
Q2 2018

Aug 09, 2018

BUY
$3.57 - $4.85 $16,065 - $21,825
4,500 Added 6.63%
72,411 $300,000
Q1 2018

May 14, 2018

BUY
$3.67 - $5.19 $65,693 - $92,901
17,900 Added 35.79%
67,911 $270,000
Q4 2017

Feb 09, 2018

BUY
$3.01 - $4.9 $150,533 - $245,053
50,011
50,011 $219,000

Others Institutions Holding FLGT

About Fulgent Genetics, Inc.


  • Ticker FLGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 30,265,800
  • Market Cap $609M
  • Description
  • Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions...
More about FLGT
Track This Portfolio

Track Royce & Associates LP Portfolio

Follow Royce & Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.